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Abstract
The shortage of organs for transplantation is of critical importance worldwide. 
Xenotransplantation or xeno-embryonic organ transplantation can stably supply 
organs and is considered to be an established alternative treatment. Regenerative 
medicine is another option, and recent advances in stem cell research have enabled 
the reproduction of miniature organs, called organoids, derived in vitro from 
human induced pluripotent stem cells. However, the in vitro production of large 
and complex organs that can efficiently function in vivo is not yet accomplished. 
We proposed a novel strategy for xenotransplantation in which a chimeric kidney is 
constructed by injecting human nephron progenitor cells into a porcine embryonic 
kidney, thereby eliminating pig nephron progenitor cells and allowing transplanta-
tion into a human and long-term survival. In this chapter, we discussed advantages 
and pitfalls of xenotransplantation and xeno-embryonic kidney transplantation. 
Recent attempts of human organoids and blastocyst complementation were 
reviewed. Finally, we proposed our novel xeno-regenerative therapeutic strategy.
Keywords: kidney regeneration, xeno-embryonic kidney transplantation, 
organogenic niche method, nephron progenitor cell replacement system, induced 
pluripotent stem cells
1. Introduction
Currently, the only definitive treatment for end-stage organ failure is transplan-
tation. However, the global scarcity of organs is a critical challenge, necessitating 
that novel alternatives be developed. Xenotransplantation is a revolutionary therapy 
that can supply organs stably. In recent years, gene editing techniques, such as 
CRISPR/Cas9, have been developed to produce animals that generate organs at 
low risk of rejection and infection. Given that our understanding of xenogenic 
immune barriers has expanded, xenotransplantation may have a promising outlook. 
Presently, the strong antigenicity of xenogenic organs is the main barrier to xeno-
transplantation and has resulted in the development of methods of xeno-embryonic 
transplantation that use less antigenic organs. Although embryonic organs are 
prematurely transplanted, they can mature in vivo in a self-sustaining manner to 
perform their function. Xeno-embryonic organs, therefore, have some utility as a 
scaffold for the regeneration of human organs.
Regenerative medicine is anticipated to be a promising alternative when tackling 
the problem of a shortfall in organ availability. Recent advances in stem cell research 
have enabled the reproduction of miniature organs called organoids, which are 
derived in vitro from human induced pluripotent stem cells (iPSCs). However, we 
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have not yet achieved in vitro reproduction of large and complex organs that func-
tion efficiently in vivo. Because kidneys comprise a three-dimensional and complex 
combination of various cell types that must perform homeostatic and endocrine 
functions, in vitro regeneration of the kidneys is particularly challenging compared 
with other organs. To overcome this challenge, we sought to use xeno-embryonic 
kidneys as a scaffold for development of human progenitor cells. By transplanting 
exogenous nephron progenitor cells (NPCs) into the metanephric mesenchyme of a 
xenogenic fetus, we aimed to regenerate whole neo-kidneys from the transplanted 
NPCs via their xenogenic development program. Specifically, we propose a novel 
xenotransplantation strategy wherein a chimeric kidney is constructed by injecting 
human NPCs into a porcine embryonic kidney and transplanted into a human after 
eliminating pig NPCs.
In this chapter, we discussed advantages and pitfalls of xenotransplantation and 
xeno-embryonic kidney transplantation. Recent attempts of human organoids and 
blastocyst complementation were reviewed. Finally, we proposed our novel xeno-
regenerative therapeutic strategy.
2. Kidney xenotransplantation
Xenotransplantation is a revolutionary therapy used to solve the problem of 
organ shortage. The concept has existed for more than 100 years, with the first 
kidney xenotransplantation performed in 1906. In this procedure, a pig kidney was 
heterotopically transplanted into a patient with renal failure but had to be removed 
after 3 days because of vessel thrombosis [1]. Subsequent attempts at renal xeno-
grafting failed, and the practice was abandoned. However, xenotransplantation re-
emerged as an option following the development of powerful immunosuppressive 
agents. In 1964, the kidney of a chimpanzee was successfully transplanted into a 
patient with renal failure and functioned for 9 months before the patient ultimately 
died of pneumonia [2]. Nonhuman primates were often used as a xenograft source 
at this time because the similarities between species produced good outcomes. 
However, this practice was abandoned because of the relative scarcity of nonhu-
man primate sources, concerns about disease transmission, and ethical issues. By 
contrast, pigs are almost limitlessly available as a transplant source, and their kid-
neys are similar in size and physiological function to those of humans. At present, 
porcine kidneys are therefore considered a suitable xenotransplantation source [3].
Nevertheless, using porcine kidneys in xenotransplantation presents some 
problems that must be addressed. The most critical problem is the presence of 
α-galactose-1,3-galactose (Gal). This galactose moiety is added to cell surface 
sugars in swine by α-1,3-galactosyltransferase (GalT), whereas primates, including 
humans, do not inherit GalT and possess anti-Gal antibodies as natural antibodies 
[4]. When a pig kidney is transplanted into a primate, anti-Gal antibodies bind to 
the Gal antigen expressed on porcine vascular endothelial cells, activate human 
complement, and cause hyperacute vascular rejection that immunosuppressants 
alone cannot prevent. Recently, genetically modified pigs with low risk of rejection 
potential were created with gene editing technology; a representative example is 
the GalT-knockout (KO) pig [5]. Given that these transgenic pigs do not express 
Gal, the anti-Gal antibody in primates does not react with them. Pigs expressing 
human complement regulatory proteins (e.g., human CD55 and CD46) that sup-
press human complement activation have also been reported [6, 7]. Other attempts 
have been made to overcome the risk of coagulation dysfunction by introducing 
human coagulation-regulatory genes, such as thrombomodulin, into pigs [8]. 
Moreover, pigs are now available that have various combinations of these genetic 
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modifications, and research is ongoing as to the optimal combination for transplan-
tation. Actually, it is technically possible to produce pigs with multiple KO genes 
and multiple transgenes simultaneously [9, 10]. One such example is the double 
gene KO pig including GalT-KO that expresses three human complement regulatory 
genes and two anti-inflammatory genes; however, this combination might not yet 
be complete [10].
Improved immunosuppressive regimens are also contributing to the progress 
seen in xenotransplantation of pig kidneys. There has been particular interest in 
blockade inhibiting the CD40/CD154 pathway, with anti-CD40 or anti-CD154 
antibody therapy contributing significantly to a prolongation of renal xenograft 
survival [11, 12]. In 2019, a GalT-KO kidney expressing CD55 was transplanted from 
pig to rhesus macaque and had the longest survival of life-sustaining xenograft to 
date (499 days) [13]. However, although hyperacute rejection by Gal antibodies 
has been largely overcome, late antibody-mediated injury by non-Gal antibodies 
remains a problem. Another problem that needs to be resolved is recipient death 
from infection due to strong immunosuppression [12].
The possibility of zoonotic infection cannot be ignored in xenotransplantation. 
Given that pigs can be bred in pathogen-free environments, the risk of acquiring 
zoonotic infections is lower than that of primates. However, the risk of porcine 
endogenous retrovirus (PERV) that integrates along chromosomes cannot be 
removed by this approach. In previous research, it was reported that PERV can 
infect human cells in vitro [14]. In 2015, CRISPR/Cas9 succeeded in knocking out 
62 copies of the PERV pol gene in porcine cells [15], and in 2017, a PERV-free pig 
was produced [16].
As shown in this section, the measures taken against rejection and infection 
mean that kidney xenotransplantation is rapidly approaching clinical reality.
3. Xeno-embryonic kidney transplantation
The use of xeno-embryonic transplantation may broaden the organ pool. This 
approach seems to benefit from a lower risk of rejection compared with adult organ 
transplantation, making a potentially invaluable therapeutic resource. Although an 
embryonic organ is transplanted prematurely, it can mature in a self-sustaining way 
in vivo to become functional. Xeno-embryonic organs may be particularly useful as 
a scaffold for the regeneration of human organs.
Metanephroi have generally been used for embryonic kidney transplantation [17] 
because this form is already committed to becoming a kidney. When transplanted 
into a recipient, the metanephroi is free to differentiate and mature into a whole kid-
ney. The transplanted metanephroi promotes angiogenesis, encouraging host blood 
vessel infiltrating, thus resulting in glomeruli that are composed of host-derived 
vasculature [18]. The developed metanephroi produces urine, and anastomosing 
the ureter of the metanephroi and the ureter of the host has been shown to prolong 
the survival time of host anephric rats [19]. Moreover, the developed metanephroi 
acquires endocrine function, producing both renin and erythropoietin [20, 21].
Conveniently, the metanephroi is a fetal organ that may have low immunoge-
nicity, potentially making it especially suitable for transplantation. Contrasting 
with adult grafts that already have the donor vessels, the avascular metanephroi is 
only vascularized by host vessels after it is transplanted. Thus, humoral immunity 
to donor endothelial cells is less likely to occur when using the metanephroi for 
transplantation [22]. Additionally, we can expect a reduced expression of donor 
antigens, such as HLA class I and II, on a developing metanephroi graft when 
compared to an adult graft [23].
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The ultimate size of the developed metanephroi appears to be imprinted during 
the early stages of embryonic development. Considering human clinical applica-
tion, pigs are an ideal resource for metanephric transplantation as with adult 
kidney xenotransplantation. In the case of allogenic porcine transplantation, the 
metanephroi on embryonic day 28 (E28) has been successfully transplanted into 
a nonimmunosuppressed recipient pig and shown to differentiate into a mature 
kidney without rejection [24]. Allogenic adult kidney grafts are easily rejected 
without immunosuppression. Transplants originating from pig embryos on E27 to 
E28 all exhibited significant growth and full differentiation, while those harvested 
on E20 and E25 failed to develop and only differentiated into few glomeruli and 
tubules, together with other derivatives, such as blood vessels, cartilage, and bone 
[25]. This indicates that metanephroi that are too immature may be incompletely 
pre-programmed and may differentiate into nonrenal structures. However, age-
dependent graft growth and survival in allogenic rats was shown to be optimal 
from E15 and worsened progressively for metanephroi obtained on E16 to E21. The 
developed metanephroi obtained on E15 showed maturation of renal elements and 
no sign of rejection, whereas those obtained on E20 had a poor renal architecture 
and a dense lymphocytic infiltrate [26]. Importantly, there appears to be an optimal 
window for harvesting metanephroi to obtain good transplantation outcomes.
Successful xeno-metanephric transplantation has been reported previously. In 
an important study, E28 pig metanephroi or adult kidneys were transplanted into 
recipient rats with and without immunosuppression. Those transplanted into 
nonimmunosuppressed rats showed tissue rejection, whereas those transplanted 
into hosts treated with CTLA-4-Ig underwent growth and differentiation. By 
contrast, adult kidney grafts showed disturbed morphology, necrotic tissue, 
and a high degree of lymphocyte infiltration, even when hosts were treated with 
CTLA-4-Ig [25].
The immune advantage of metanephroi over developed adult kidneys has been 
demonstrated by direct comparison of xenotransplantation into host animals 
treated with immunosuppressants. Next, it will be necessary to study the xeno-
transplantation of pig metanephroi into nonhuman primates.
In the case of xenotransplantation of pig islets, embryonic islet tissues are 
regarded as a choice for xenotransplantation with several advantages including 
reduced immunogenicity, long-term proliferative potential, and revascularization 
by host endothelium. However, the embryonic implants exhibit a delayed insulin 
response to glucose in vivo (>3 months) and limited effect on improvement of 
blood glucose level [27]. Fetal and neonatal pig islets have the higher expression 
of GAL and will be more susceptible to xenorejection than adult pig islets [28, 29]. 
Therefore, adult pig is regarded as the primary donor source of islet xenografts, 
which can supply an adequate amount of viable islet cells and start functioning 
immediately after implantation.
4. Kidney organoids derived from pluripotent stem cells (PSCs)
The field of stem cell research is growing at a rapid pace. The reproduction of 
organoids derived from human iPSCs in vitro is already possible in several organs, 
including the optic cup, intestines, and liver [30–32]. Although embryologic 
kidney development is complicated, the reproduction of kidney organoids has 
been reported. Kidneys arise from metanephroi, which develop via the reciprocal 
interaction between the metanephric mesenchyme, containing NPCs and stromal 
progenitor cells, and the ureteric bud. Takasato et al. reported simultaneously 
inducing metanephric mesenchyme and ureteral buds from human iPSCs to 
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produce kidney organoids. The generated organoids contained nephrons associated 
with a collecting duct network surrounded by renal interstitium and endothelial 
cells [33]. Taguchi et al. also reported the successful differentiation of human 
iPSCs into NPCs and ureteric buds in vitro, by repeating the development of the 
metanephric kidney [34, 35]. Additionally, they reconstructed kidney organoids 
with higher-order structures, containing embryonic branching morphogenesis, by 
reaggregating NPCs and ureteric buds derived from mouse PSCs and stromal pro-
genitor cells from mouse embryos. However, a method for differentiating human 
iPSCs into stromal progenitor cells is yet to be established. Furthermore, neither 
of the developed kidney organoids have a urine drainage system, and both are too 
small to function in vivo. Therefore, generating functional kidneys in vitro remains 
a challenge before this research has translational potential.
5. Blastocyst complementation
As an alternative to in vitro directed differentiation of iPSCs, previous studies 
have considered methods of regenerating solid organs from transplanted exogenous 
cells to function in vivo by borrowing a xenogenic development program. One such 
method is blastocyst complementation. When PSCs are transplanted into blasto-
cysts, which are early animal embryos, chimeras containing blastocysts and PSCs 
are formed. When PSCs are injected into blastocysts that have undergone genetic 
manipulation not to generate a target organ, the missing organ is formed from 
the injected PSCs by systemic chimera formation. Using the method of blastocyst 
complementation, kidneys derived from mouse iPSCs have been regenerated in sall1 
knockout mice that lack kidneys [36]. Successful kidney regeneration has also been 
derived from mouse iPSCs in sall1 knockout rats [37]. Therefore, this generation 
mechanism appears to have interspecies compatibility. The renal lineage cells were 
derived from the injected PSCs, whereas nonrenal lineages such as blood vessels 
and stromal cells in kidneys were chimeric for both blastocyst cells and PSCs. 
Recently, mouse PSC-derived vascular endothelial cells were regenerated into Flk-1 
knockout mice, lacking a key gene for vascular endothelial development [38]. By 
simultaneously disrupting Flk-1 and genes required for genesis of the target organ, 
rejection-free organs could be generated from patient-specific iPSCs. The size of 
the regenerated organ will be affected by the size of the host animal blastocyst. 
Successful allogenic blastocyst complementation has been shown to regenerate large 
organs in pancreas-deficient pigs [39].
Given that human iPSCs fundamentally lack the ability to form chimeras, blasto-
cyst complementation cannot be applied directly to humans. Inducing the expres-
sion of anti-apoptotic genes could give some chimera-forming ability to human 
iPSCs [40, 41], but the long-term safety would require clarification because these 
are also recognized oncogenes. Another issue is that basing this method on systemic 
chimera formation leads to the serious ethical concern of chimera formation in host 
gametes or neural tissue other than the target organs. The introduction of the het-
erologous cells during insemination must be thoroughly considered for the loss of 
the personal identity of a living being [42]. If these problems can be resolved, such a 
method that can produce organs that function in vivo would be highly significant.
6. Organogenic niche method and NPC replacement system
We have developed an organogenic niche method that utilizes a xenogenic devel-
opment program. In this method, exogenous organ progenitor cells are transplanted 
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into the region of the xenogenic fetus where the target organ develops. The trans-
plantation of progenitor cells into host tissue matched by developmental stage may 
be critical for efficient cell grafting. In our experiments, we first injected human 
mesenchymal stem cells (hMSC) expressing glial cell line-derived neurotrophic fac-
tor into the embryonic rat site where budding of the ureteric bud occurred. Second, 
the transplanted host rat embryo was grown in a whole-embryo culture system [43]. 
Third, the transplanted hMSCs were integrated into the metanephroi and differen-
tiated into tubular epithelial cells, interstitial cells, and glomerular epithelial cells 
[44]. Fourth, we transplanted the developed metanephroi into recipient rats. Using 
this approach, the metanephroi integrated with the vessels of recipient rats and the 
vascularized nephrons (derived from hMSCs) regenerated. The neo-kidney derived 
from hMSCs also produced urine by filtering the host blood, and the level of urea 
nitrogen and creatinine in the urine was higher than that of the host serum [45], 
and it also secreted human erythropoietin in response to host anemia [46]. Thus, we 
successfully regenerated human cell-derived neo-kidneys with in vivo function. As 
described, instead of PSCs, we used stem cells or progenitor cells that have limited 
potency. These cells were only locally transplanted into embryos at mid-to-late 
gestational ages, thereby ensuring that chimera formation only occurs in the kidney 
and avoiding any potential ethical concerns.
Existing native host cells inhibit the engraftment of transplanted donor cells. 
We recently developed a new method combining an organogenic niche with elimi-
nating host NPCs to increase the efficiency of donor cell engraftment [47]. In this 
method, we used transgenic mice in which the diphtheria toxin receptor (DTR) 
was specifically expressed on Six2-positive NPCs (Six2-iDTR transgenic mouse). 
Rodents such as mice and rats naturally lack the DTR, so Six2-positive NPCs 
selectively undergo apoptosis with the administration of diphtheria toxin. When 
donor mouse NPCs are transplanted into host mouse metanephroi, they became 
chimeric with the existing native host NPCs, and contribution rate of the donor 
cells was 30% of cap mesenchyme cells. Administering diphtheria toxin eliminated 
the host mouse NPCs and allowed 100% replacement with donor mouse NPCs 
that could generate neo-nephrons [47] (Figure 1). In this way, we succeeded in 
achieving full replacement with heterogeneous donor rat NPCs. Importantly, we 
revealed that nephrons derived from rat NPCs could connect to the host mouse 
collecting ducts, even when nephrons and collecting ducts were heterogeneous. 
Next, we examined the possibility of in vivo regeneration of interspecies kidneys 
Figure 1. 
Schematic of the drug-induced cell elimination system to exchange native NPCs with exogenous NPCs.
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using NPC replacement. In subsequent research, we successfully regenerated rat 
nephrons using the Six2-iDTR mouse metanephroi as a scaffold in recipient rats 
receiving immunosuppressive therapy. We showed that neo-kidneys were vascular-
ized by blood vessels originating from the recipient rats using the species-specific 
antibody for detection. Furthermore, we injected fluorescent-labeled dextran into 
the recipient rats, and the accumulation of dextran in Bowman’s space of neo-
glomeruli and in the lumen of neo-tubules was confirmed. Our findings confirmed 
that neo-kidneys were incorporated into blood circulatory system of recipients, 
resulting in functional neo-glomeruli filtration [48].
In the future, we aim to use this system of kidney regeneration with pig fetuses 
as the bioreactor and human iPSC-derived NPCs as the cell source. It is not difficult 
to supply a cell source because protocols for inducing NPCs from human iPSCs 
have already been developed [33, 34]; additionally, expansion of NPC culture is 
possible [49, 50]. A fundamental problem with our proposals is that human cells 
permanently express DTR and can undergo apoptosis when treated with diphtheria 
toxin. Therefore, the DTR system cannot be applied directly to humans. Recently, 
we developed a new transgenic model to ablate NPCs using an alternative drug that 
does not affect human cells (unpublished data).
7. Stepwise peristaltic ureter system
Although transplanted metanephroi can produce urine, they lack a urine 
excretion pathway, gradually become hydronephrotic, and cease functioning. 
Neo-kidneys regenerated using metanephroi as a bioreactor may also follow the 
same mechanism. Recently, we developed a urine excretion strategy for embryonic 
kidneys generated by stem cell methods.
The ultimate size of a metanephric graft is determined by the size of the source 
animal. Pigs are therefore considered a suitable resource from this perspective. To 
eliminate the potential for rejection, we transplanted metanephroi from cloned pig 
fetuses into syngenic hosts. All transplanted metanephroi differentiated success-
fully into mature kidneys, growing to 5–7 mm in length by 3 weeks. After 5 weeks, 
metanephroi grew to more than 1 cm and retained urine in the developed ureters, 
and after 8 weeks, they grew to about 3 cm and started to develop hydronephrosis 
as urine production increased [51]. Ureteral primordia start peristalsis during the 
embryonic stage and normally excrete urine into the bladder, and this sustained 
urine excretion may be important for normal development.
To delay the onset of hydronephrosis and to promote the growth of metanephric 
grafts, we transplanted metanephroi with ureters and a bladder (MNB) into a 
recipient animal. After 4 weeks, hydronephrosis occurred in the group with normal 
metanephroi transplants but not in the group with MNB transplants. In the MNB 
group, urine retention in the bladder was observed. Histopathologic examination 
also showed more pronounced tubular luminal dilation and interstitial fibrosis, and 
greater reductions in the number of glomeruli, in the metanephroi group than with 
the MNB group. Moreover, urine volumes and urinary levels of urea nitrogen and 
creatinine were higher in the MNB group than in the metanephroi group.
Furthermore, we demonstrated the generation of a urine excretion channel 
in MNB by using the stepwise peristaltic ureter (SWPU) system. Briefly, at an 
appropriate time, we connected the host ureter to the MNB graft containing urine 
produced by the metanephroi. The SWPU system allowed for continuous urine 
drainage from the developed bladder of the MNB into the recipient bladder via the 
recipient ureter. Even 8 weeks after transplantation, the MNB showed no hydrone-
phrosis and had maintained mature renal structures, such as glomeruli and renal 
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Figure 2. 
Schematic of our novel xeno-regenerative therapeutic strategy for kidney regeneration.
tubules. The levels of urea nitrogen and creatinine were much higher in the urine 
from the MNB than in the sera of recipients. Finally, the SWPU system significantly 
prolonged the lifespan of anephric rats in the MNB group compared with the 
nontransplanted group.
In a previous study, researchers demonstrated that they could create a urinary 
pathway by directly connecting the ureter of the transplanted metanephroi to the 
ureter of the host (ureteroureterostomy) to prolong the short-term survival of 
anephric rats [19]. However, the SWPU system is more efficient than ureteroure-
terostomy in terms of preventing hydronephrosis and allowing maturation of the 
metanephroi. Surgery for the SWPU system is also easier than that for uretero-
ureterostomy because the bladder of the MNB expands with urinary retention. 
Furthermore, we can join two metanephroi to a host ureter using the SWPU system, 
whereas it is difficult to connect two metanephroi to the host ureter. In a previous 
study, it was reported that the survival time in anephric rats correlated with the total 
volume of the grown metanephroi [52]. It is possible that the SWPU system is more 
effective than the conventional method in prolonging survival time for this reason.
Assuming that MNBs can be used as a scaffold for kidney regeneration before 
transplantation into patients with renal failure, we investigated the effects of host 
renal failure on the structure and activity of the transplanted MNB. Uremic condi-
tions were reproduced using a 5/6 renal infarction rat model, and 4 weeks after 
transplantation, the developed bladder was successfully anastomosed to the host 
ureter. At 8 weeks after transplantation, histological analysis showed the presence 
of mature glomeruli and tubules in the groups with and without renal failure. There 
were also no differences between these groups in terms of survival in anephric 
host rats, indicating that the grafts were responsible for prolonging host survival, 
even under renal failure conditions [53]. The results of this study demonstrate 
that a transplanted MNB can grow and function effectively, even under uremic 
conditions.
The use of MNB as a kidney regeneration scaffold can provide new treatment 
for patients with renal failure. We assume that the SWPU system will be applicable 
to human neo-kidneys regenerated via the NPC replacement system, using a pig 
MNB as a scaffold to establish the urinary excretion pathway. In brief, human 
iPSC-derived NPCs may be injected into the metanephroi of porcine fetuses that 
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are genetically manipulated to have an NPC elimination system. Human nephrons 
may then regenerate in porcine metanephroi by eliminating the porcine NPCs 
and replacing them with human NPCs. The MNB that has human kidneys will be 
transplanted into patients with end-stage renal disease, and an excretion pathway 
will be constructed. In this case, the regenerated kidneys will be of human origin, 
but the ureters and bladder of MNB will be of porcine origin (Figure 2). Although 
further investigation is required, we assume that replacing nephrons, which are the 
main targets to rejection, could decrease antigenicity.
8.  Regenerative potential of iPSCs derived from patients with renal 
failure
The use of iPSCs generated from patients holds promise for tailored therapy that 
uses patient-derived cells, tissues, or organs. In clinical settings, it is desirable to 
use patient-derived iPSCs as the cell source for neo-kidneys to circumvent immune 
rejection. However, because uremia can reduce the function of stem cells, it may be 
problematic to use stem cells derived from patients in renal failure. Previous studies 
have shown that uremia causes many toxic effects, including reduced proliferation 
capacity, abnormalities of differentiation, and angiogenic dysfunction in stem cells 
[54, 55]. We previously reported that gene and protein expression of p300-/CBP-
associated factor was significantly suppressed and that in vivo angiogenesis activa-
tion was decreased in hMSCs derived from patients with end-stage renal disease 
(ESRD) [56]. However, there have been no reports about the biological properties 
of iPSCs derived from patients with ESRD. In our recent study, iPSCs derived from 
patients with ESRD could differentiate into NPCs as efficiently as iPSCs derived 
from healthy controls. Moreover, NPCs derived from patients with ESRD showed 
the potential to become mature and vascularized nephrons in vivo, similar to the 
process in healthy control [57]. These findings suggest that iPSCs from patients 
with ESRD may still be a useful cell source for kidney regeneration.
9. Conclusions
In this chapter, we have described several potential alternatives to allotransplan-
tation, focusing on our novel xeno-regenerative therapeutic strategy for kidney 
regeneration. Although there are issues to be overcome with the treatment alterna-
tives that are being developed, recent advances in genetic recombination technol-
ogy and stem cell research may make them available in clinical practice. We have 
addressed the development of genetically modified pigs that possess an NPC elimi-
nation system and have performed experiments with NPCs derived from human 
iPSCs. To date, each step of our proposed strategy for kidney regeneration has 
been accomplished successfully in rodent models. This includes the regeneration of 
kidneys derived from transplanted NPCs via NPC replacement, the transplantation 
of regenerated kidneys into host animals, and the construction of a urine excre-
tion pathway (i.e., the SWPU system). Looking to the future, we aim to complete a 
series of studies to allow transplantation from pig to human, which should facilitate 
the translation of our strategies to clinical settings.
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